2014-04-08

[DIV28SUPER] NIDA Neuroscience Update April 8, 2014

I.                    Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2)  RFA-DA-15-006   

II.                  Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) RFA-DA-15-007

III.                Effects of Cannabis Use and Cannabinoids on the Developing FOAs

IV.                NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1) RFA-DA-15-004   

V.                  Request for Information (RFI): Availability of Data and Samples from Randomized Smoking Cessation Trials NOT-DA-14-005

VI.                Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM)  (R21/R33)

VII.              NSF Understanding the Brain portal

VIII.            NIH just released solicitation for NIH Pain Consortium Centers of Excellence in Pain Education (BAA-N01DA-15-4422)

 

Reminders:

 

IX.                BARCELONA 2014 Summer Course "Cellular Biology of Addiction" (partnered with the CSHL)

X.                  Identification of Gene Variants for Addiction Related Traits by Next-Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3) PAR-DA-14-010

XI.                NIDA has joined, RFA-HG-14-020, "Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01)".

 

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to istserv@list.nih.govmailto:listserv@list.nih.gov,

 Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

---------------------------------------

I.        Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2)  RFA-DA-15-006    Application due dates: August 18, 2014, August 18, 2015, August 18, 2016, by 5:00 PM local time of applicant organization.

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. The Genetic Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction.   The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance abuse. 

--------------------

II.      Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) RFA-DA-15-007

Application due dates: November 12, 2014, November 12, 2015, November 14, 2016, by 5:00 PM local time of applicant organization.

Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS.  The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support research approaches for substance using populations with or at risk for HIV/AIDS that may lead to improved preventive interventions, improved therapies and/or long term retention in care, and ultimately, eradication of HIV.

----------------------------------------------

III.    Effects of Cannabis Use and Cannabinoids on the Developing Brain

 

Standard dates apply, by 5:00 PM local time of applicant organization.R01: http://grants.nih.gov/grants/guide/pa-files/PA-14-163.html

R21: http://grants.nih.gov/grants/guide/pa-files/PA-14-162.html

R03: http://grants.nih.gov/grants/guide/pa-files/PA-14-164.html

These Funding Opportunity Announcements (FOAs) encourages Research Project Grant applications from institutions and organizations that propose to study the effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri-, post-natal development through young adulthood in animal models and humans. Topics of interest pertaining to this FOA include, but are not limited to: molecular and cellular mechanisms of cannabis/cannabinoid effects on the developing brain; long term functional consequences of cannabis/cannabinoid exposure on learning and memory, cognitive and emotional development.

 

-------------------------------------------

 

IV.    NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1) RFA-DA-15-004   

Application due dates: July 29, 2014, July 29, 2015, July 29, 2016, by 5:00 PM local time of applicant organization.

 

The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers.  The term "avant-garde" is used to describe highly innovative approaches that have the potential to be transformative.  The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others.  The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

 

--------------------------------

 

V.     Request for Information (RFI): Availability of Data and Samples from Randomized Smoking Cessation Trials NOT-DA-14-005 Response requested by May 1, 2014

 

The National Institute on Drug Abuse and the National Cancer Institute seek information about the availability of data and/or biological samples from randomized controlled trials of smoking cessation therapies.   If you have conducted a randomized clinical trial, we request that you send information about the clinical trial.  Examples of the type of information that would be helpful include:  1) The Program Director/Principal Investigator and Assistant contact information; 2) publication and or clinical trial registry IDs; 3) the number of trial participants randomized with data available for intent-to-treat analysis; 4) the types of bio-specimens available and the number of research participants with these bio-specimens  5) the number of bio-specimens or DNA samples with data available for intent-to-treat analyses; 6) amount of DNA available per research participant; 7) trial design characteristics; 8) Baseline demographics and behavior; 9) trial Sponsors

 

The information gathered will assist in evaluating the feasibility of combining data and samples for a pharmacogenomics analysis of smoking cessation based on the availability of these samples. 

 

----------------------------------

 

VI. Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM)  (R21/R33)

Standard dates apply, by 5:00 PM local time of applicant organization.

 

This announcement is intended to encourage early career chemists (or chemists new to NIH) to develop probes that aid basic research investigations on drug abuse and/or identify new or better templates as lead compounds with potential for conducting structure activity relationship (SAR)-function studies. Importantly, this includes the identification of new chemical entities (NCEs) with therapeutic potential for drug abuse and addiction.

 

-----------------------------------------

 

VII.          NSF Understanding the Brain portal

NSF has launched an Understanding the Brain portal at http://www.nsf.gov/news/special_reports/brain/This site hosts information about NSF's neuroscience-related funding opportunities, activities, and news.

NSF also now has a whole YouTube channel dedicated to videos about neuroscience and brain research http://www.youtube.com/watch?v=SGuAO1SkZXk&feature=youtu.be

 

-----------------------------------------------

 

VIII.  NIH just released solicitation for NIH Pain Consortium Centers of Excellence in Pain Education (BAA-N01DA-15-4422)  The National Institutes of Health is soliciting proposals to develop pain management training and educational resources for health professional schools, such as medical, dental, nursing, mental health, physical therapy, and pharmacy to advance the assessment, diagnosis, and safe treatment of pain.  Contract awardees will be designated as Centers of Excellence in Pain Education (CoEPEs), as part of the NIH Pain Consortium (www.painconsortium.nih.gov).

Offerors should submit questions about the BAA and a "Proposal Intent Response Form" (see BAA Attachment 2, which is PDF page 88)  by Wednesday, April 16 to Kara Anderson (kara.anderson@nih.gov) and Ryan Cleary (clearyrc@mail.nih.gov).  Proposals are due by 3 p.m. Eastern Time on May 19, 2014.

 

--------------------------------------------

 

Reminders:

 

IX. BARCELONA 2014 Summer Course "Cellular Biology of Addiction" (partnered with the CSHL) to be held July 13-20, 2014, Barcelona, Spain.  Application date April 18, 2014.   Scholarships Available. To apply click here.

 

This event is organized by the University Pompeu Fabra (UPF, Spain) and the Cold Spring Harbor Laboratory (CSHL, USA), and is supported by the National Institute on Drug Abuse (NIDA). The conference will follow the current CSHL course format (see the 2013 edition at http://meetings.cshl.edu/courses/2013/c-drug13.shtml).

 

-------------------------------------------------

X. NIDA has joined, RFA-HG-14-020, "Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01)".

 

In response to the spectacular opportunities and immense challenges presented by the dawning era of "Big Data" in biomedical research, the NIH has developed the Big Data to Knowledge (BD2K) initiative. The purpose of this BD2K U01 Funding Opportunity Announcement (FOA) is to solicit development of innovative analytical methods and software tools in the four topic areas of data compression/reduction, data visualization, data provenance, and data wrangling as part of the overall BD2K initiative. It is not expected that software and methods developed under this FOA will be fully hardened, but rather that investigators show a novel approach to a difficult problem and show some proof-of-concept for this new approach using relevant biomedical Big Data. There is no PI citizenship restriction. It has a single submission date, May 19, 2014 and earliest funding will begin in March 2015. The projects may last for three years. Annual direct costs are a maximum of $300K. Please see our notice of participation at: http://grants.nih.gov/grants/guide/notice-files/NOT-DA-14-008.html.

 

---------------------------------------

 

XI. Identification of Gene Variants for Addiction Related Traits by Next-Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3) PAR-DA-14-010   Application due dates: June 30, 2014; October 31, 2014; June 30, 2015; October 31, 2015; June 30, 2016; by 5:00 PM local time of applicant organization.

This announcement encourages applications for projects aimed at discovery of gene variants in either new or previously developed selectively bred animal models through the use of Next-Gen Sequencing technologies. The proposed projects should be based on data demonstrating the relevance of the selected traits to addiction and the practicality of the selective breeding either directly, for example by the existence of the selected strain, or indirectly. The applicants may employ previously selectively bred animals, re-derived strains, or strains selected for some new phenotype or beginning with a novel progenitor population. Investigators with existing established selectively bred animal models may also propose mapping strategies for gene variations in combination with Next-Gen Sequencing.

 

-------------------------

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to istserv@list.nih.govmailto:listserv@list.nih.gov,

 Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

 

 

 

 

 

 

 

 

 

 

 

 

1 comment:

Gurcharan Kaur said...

I am Gurcharan Kaur from New York. I was in trouble when doctor told me that I have been diagnosed with HIV... I though about my children and my husband, I know my children will face a serious problem when I'm gone, I lost hope and I wept all day, but one day I was surfing the internet I found Dr. Oraede's contact number. I called him and he guided me. I asked him for solutions and he started the remedies for my health. Thank God, now everything is fine, I'm cured by Dr. Oraede herbal medicine, I'm very thankful to Dr. Oraede and very happy with my hubby and children. email him on dr.oraedespellhome@hotmail.com; dr.oraedespellhome@gmail.com, call him on +2349038604218, email me on catwrightkaur@gmail.com www.dr-oraede.webs.com
http://oraede-herbs-cure-hiv.blogspot.com

Post a Comment